In February 2024, former J&J employees brought a class action lawsuit in federal court alleging that (1) J&J and other group health insurance plan fiduciaries breached their duties under ERISA by failing to take the proper measures to ensure its plan costs were reasonable
The conversation around GLP-1 medications in 2026 has reached a fever pitch
As we look ahead, here are a couple of key developments to watch for that will expand your future options: More Approved Oral Versions: Expect the FDA to approve new oral medications, including higher doses of existing drugs and entirely new compounds like Orforglipron
Third-Party Testing Because the FDA does not regulate supplements, third-party testing provides independent verification of a NMN supplements safety, purity, and label accuracy
High-quality liposomal glutathione typically demonstrates controlled particle size distribution, stable zeta potential, and high encapsulation efficiency for consistent delivery performance